The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
What similarly acting projects are still unpartnered?
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
After a conference lacking the wow factor, biotech winners and losers emerge.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.